Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Brown University researchers have identified a promising new approach that may help to restore vision in people affected by macular degeneration and other retinal disorders.
New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis pigmentosa. No therapy exists for this rare inherited disease, which starts affecting vision from childhood.
Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa.
Researchers have developed lab-grown pig retinal organoids to test stem cell replacement therapies for diseases that damage the eye's light-sensing photoreceptors.
A clinical trial that tested an experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients, and there was a high proportion of complete or partial success.
Researchers at the Jackson Laboratories used mice with nine different genetic backgrounds to identify factors influencing eye aging, paving the way for eye-based diagnostics for neurodegenerative diseases